November 2, 2018 08:09 AM EDT

Tuning in: Intensity's immune-based chemo delivery tech attracts backing of British billionaire Jim Mellon

Amber Tong

In cancer treatment, chemotherapy and immunotherapy are often seen as completely separate, if complementary, categories of treatments. A tiny biotech out of Westport, CT now …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Tuning in: Intensity's immune-based chemo delivery tech attracts backing of British billionaire Jim Mellon

Amber Tong

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Tun­ing in: In­ten­si­ty's im­mune-based chemo de­liv­ery tech at­tracts back­ing of British bil­lion­aire Jim Mel­lon

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Tuning in: Intensity's immune-based chemo delivery tech attracts backing of British billionaire Jim Mellon